MTOR and Wilson disease: WD-NETs are mostly slow-growing indolent tumors whose treatment is based on targeting somatostatin receptors with somatostatin analogs or peptide radionuclide receptor therapy [31,32,33,34,35], the mTOR pathway with everolimus [36,37,38,39,40], or neoangiogenesis with sunitinib in panNETs [41], while chemotherapy is usually deferred to later lines.